Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-12-18 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - TLX 9 pages 35.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the issuance and conversion of options into ordinary fully paid shares, including numbers, issue dates, and whether the securities are cash consideration or cashless exercise. The document is a regulatory announcement about new securities being quoted, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the securities issued and their terms. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2022-12-18 English
Cleansing Notice 1 page 141.6KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and details share issuance dates and quantities. The content is a regulatory announcement about share issuance and compliance with disclosure requirements, not a full financial report or detailed capital update. The document length is short (1506 characters) and it serves as a formal notification rather than a report or presentation. This fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories like Capital/Financing Update or Share Issue/Capital Change, since it is a statutory notice under the Corporations Act rather than a direct capital raising announcement or share issue event notice.
2022-12-18 English
App 3Y Change in Director Interests - T Olsen 2 pages 206.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's acquisition of shares and share appreciation rights, including dates, quantities, and prices. This is a report of personal share transactions by a company director, which fits the definition of 'Director's Dealing'. The document length is 3587 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or any other type of filing. Therefore, the correct classification is 'DIRS'.
2022-12-14 English
Leadership Changes, including Company Secretary Appointment 2 pages 160.9KB
Board/Management Information Classification · 95% confidence The document is an ASX release announcing executive leadership appointments and a change of company secretary at Telix Pharmaceuticals Limited. It focuses on management changes and succession planning, with no financial statements, earnings data, or detailed financial analysis. The content is typical of a Board/Management Information announcement, specifically about changes in senior management roles. There is no indication that this is a full annual or interim report, audit report, earnings release, or any other financial or regulatory filing. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2022-12-04 English
Release of shares from voluntary escrow 2 pages 268.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX release titled 'Release of Shares from Voluntary Escrow' by Telix Pharmaceuticals Limited. It announces the release of shares from voluntary escrow in accordance with ASX Listing Rule 3.10A. The content focuses on share release details and does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement about share escrow release, not a financial report or detailed investor presentation. The document length is about 5,233 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2022-11-27 English
Application for quotation of securities - TLX 10 pages 38.6KB
Regulatory Filings Classification · 95% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the issuance and conversion of options into ordinary fully paid shares, including the number of securities, issue dates, exercise prices, and whether the securities rank equally with existing shares. The document is regulatory in nature, related to the listing and quotation of securities, and does not contain financial statements, earnings data, or management commentary. It is not an announcement of a report publication but a formal regulatory filing about securities quotation. Therefore, it fits best under the category of Regulatory Filings (RNS).
2022-11-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.